Share this video  

ASCO GI 2022 | HIMALAYA: tremelimumab + durvalumab in unresectable HCC

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of HIMALAYA, (NCT03298451), an open-label, randomized, multicenter, Phase III study evaluating single dose tremelimumab plus regular intervals of durvalumab versus standard of care (SOC) sorafenib (STRIDE regimen) in patients with unresectable hepatocellular carcinoma. In conclusion, the results show the STRIDE regimen is a notably improved treatment option for patients with uHCC, both in terms of efficacy and safety and therefore a promising new first-line SOC for this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.